Fig. 2.

The effect of acute modafinil on the amount of sleep-wake stages in active phase in R6/2 and wild-type mice. Modafinil (25, 50, and 100 mg/kg; i.p.) was administered at the beginning of active phase (11 am) and the time spent awake (a), in non-rapid eye movement sleep (NREMS, b), and in rapid eye movement sleep (REMS, c) was measured in wild-type (WT), and in R6/2 mice aged 12 weeks and 16 weeks. Data are presented as (mean ± SEM) percent changes in the time spent in each vigilance stage relative to the WT vehicle group. *p < 0.05 and **p < 0.01 compared to the relevant vehicle treatment; ^#p < 0.05 and ^##p < 0.01 compared to the WT vehicle group